Abstract. Therapeutic criteria of Growth Hormone (GH) treatment are based on a scoring system determined by the Foundation for Growth Science. The scoring system has two criteria: criterion I includes short children with peak GH response less than 10 ng/ml in more than two provocation tests, criterion II includes short children with GH neurosecretory dysfunction.
criteria of Growth Hormone (GH) treatment are based on a scoring system determined by the Foundation for Growth Science. The scoring system has two criteria: criterion I includes short children with peak GH response less than 10 ng/ml in more than two provocation tests, criterion II includes short children with GH neurosecretory dysfunction.
There are some other cases who are considered by members of the Committee for Growth Hormone Treatment to be eligible for inclusion.
A total of 892 new cases of GH deficient children treated with rGH for more than 1 year was analysed. The therapeutic effect judged by the increase in height velocity SD score (Japanese standard) was higher in patients included by criterion I than in patients by criterion II. Among the patients by criterion I, the effect was higher in patients with mean peak GH in provocation tests less than 5 ng/ml than in patients with mean peak GH 5-10 ng/ml.
Key words: GH deficiency, GH treatment, GH neurosecretory dysfunction When human growth hormone (hGH) for treatment was purified from human pituitaries, the indication for GH treatment was limited to the patients with classical GH deficiency (GHD), whose GH responses to provocative tests were less than 5 ng/ml. Now that a large supply of human growth hormone has become available by the recombinant DNA technique, the therapeutic indication is going to spread to not only GHD but also nonendocrine short stature, chronic renal failure and Turner syndrome. Furthermore, there seems to be a discrepancy between the diagnostic and therapeutic criteria in GHD because of the continuous spectrum of GH secretion capacity from GH deficient children to normal children.
In this study, we present the therapeutic criteria for GH treatment and the evaluation of clinical response in GHD.
In Japan, the indication of growth hormone (GH) treatment is limited to GHD and Turner syndrome with GHD. The criteria for selecting the patients to be treated with GH are defined by the Committee for Growth Hormone Treatment in Criterion I is defined by more than two stimulation tests.
The difference in GH values according to the different measuring kits are corrected by using the regression equation to adjust the values to the mean of two radioimmunoassay kits, which show close values . Glucagon-propranolol and GRF tests are scored differently because of their stronger stimulation.
When the sum of points in more than two tests is equal to or more than 6 , the patients are judged fit to be treated with GH . Basically it is necessary that peak GH levels Table 4 shows the correlation between the points evaluated by Criterion I and clinical characteristics in patients with 6 points or more.
Points of Criterion I significantly correlated with height velocity, percent overweight and mean peak GH. Correlation between change in height velocity SDS and various parameters in patients with 6 points or more are summarized in Table 5 . When the patients in group 2 were further evaluated and classified into two sub-groups (Group 2A with 5 points or more; Group 2B Table 6 . Clinical characteristics and the effect of GH treatment in two groups of prepubertal patients judged by Criterion II with less than 5 points), there was no significant difference in clinical characteristics or the effect of GH treatment between the two groups, except chronological age and mean sleep GH (mean GH during 3-hour nocturnal sleep), as shown in Table 6 .
A change in height velocity SDS of at least 2.5 SD was considered to be a positive therapeutic effect. Effective treatment was noted in 71.1% of patients (634/892). When patients were divided into two groups according to points by Criterion I, effective treatment was achieved more in the group with 6 points or more (501/685, 73.1%) than in that with less than 6 points (133/207, 64.3%).
Discussion and Conclusion
We have already reported that by using the mean peak GH or more than two stimulating tests, we could characterize the patients in terms of auxological aspects and the response to GH treatment, that is to say the mean peak GH is a good indicator of the GH-deficient clinical characteristics and also a good predictor of the effect of GH treatment [1] [2] . In this study, the same analysis was made using points instead of mean peak GH, and we could show that this scoring system is also a good indicator compatible with mean peak GH. Therefore, by using the scoring system of Criterion I, those patients who show GHdeficient characteristics and may respond well to GH treatment are selected. However, we could not characterize the patients who were selected for GH treatment by Criterion II. This suggests that it is difficult to clarify the GH neurosecretory dysfunction.
